Azathioprine
Indication
For treatment of Myasthenia Gravis
Amber level 1
Brand:
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Immune system and Malignant Disease
Background
Primary care prescribers are advised not to take on prescribing of these medicines unless they have been adequately informed by letter of their responsibilities with regards monitoring, side effects and interactions and are happy to take on the prescribing responsibility. A copy of locally approved shared care guidelines should accompany this letter which outlines these responsibilities. Primary care prescribers should then tell secondary care of their intentions as soon as possible by letter so that arrangements can be made for the transfer of care
Recommendation
LSCMMG Recommendation:
Amber level 1
Reason for decision:
Shared care required
Supporting documents: